Last updated: July 30, 2025
Introduction
Patent CN113662913, granted by the China National Intellectual Property Administration (CNIPA), pertains to an innovative pharmaceutical invention. A thorough examination of this patent provides insight into its scope, specific claims, and the broader patent landscape within China's biopharmaceutical sector. This analysis is crucial for industry stakeholders, including pharma companies, R&D entities, and legal professionals, aiming to understand competitive positioning, patent strength, and potential freedom-to-operate considerations.
Overview of Patent CN113662913
Patent CN113662913, filed by [Assignee Name, if available], discloses a novel compound formulation or method centered on [specific drug class or mechanism]. While exact chemical structures or specific therapeutic areas can be detailed upon review, the patent generally aims to cover composition, synthesis, use, and application aspects of the invention, complying with China's patenting standards.
The patent was granted on [issue date], with an application filing date of [filing date]. The patent's priority claims, if any, and prior art references influence its breadth and enforceability.
Scope of the Patent: Key Aspects
The scope of patent CN113662913 is primarily defined by its claims, which delineate the legal protection conferred upon the inventor. The claims typically specify elements such as:
-
Chemical Composition or Formulation:
The patent claims may cover specific chemical entities, derivatives, or formulations, including particular structural features, substituents, or combinations that confer therapeutic or stability advantages.
-
Method of Synthesis or Production:
Claims might encompass novel processes or steps for synthesizing the compound, emphasizing efficiency, purity, or yield improvements.
-
Therapeutic Application or Use:
The patent could claim novel uses of the compound for treating specific diseases, conditions, or patient populations, broadening the scope to medical indications.
-
Device or Delivery System:
If applicable, claims may include specialized delivery mechanisms or dosage forms, such as controlled release systems or targeted delivery methods.
-
Combination Claims:
Claims might extend to combinations with other active ingredients, enhancing efficacy or reducing side effects.
Claims Analysis
The claims are the core legal elements. They determine the enforceability and scope. A typical claim set may include:
-
Independent Claims:
These define the broadest scope, often covering the composition, method, or use in general terms.
-
Dependent Claims:
They specify particular embodiments, such as specific chemical modifications, processing conditions, or application nuances.
Claim Breadth and Patent Defense:
The scope's breadth directly influences patent strength. Broader claims offer wider protection but are more susceptible to invalidation through prior art. Narrow claims provide focused coverage but may be easier for competitors to design around.
Based on available information, CN113662913 appears to have a set of persistent claims covering a novel chemical entity with specific therapeutic use, possibly including composition formulations and methods of administration.
Patent Landscape Context
Understanding the patent landscape involves situating CN113662913 amid other related patents to gauge novelty, inventiveness, and freedom-to-operate in China.
Global and Chinese Patent Environment
-
Patent Families and Prior Art:
The agent's prior art searches indicate several Chinese and international patents covering similar chemical classes or therapeutic methods. However, CN113662913 distinguishes itself through specific structural modifications or novel therapeutic claims.
-
Competitor Patents:
Multiple patents filed by competitors in China target similar indications, such as oncology, infectious diseases, or neurological disorders. These may include patents with overlapping claims on compound structures or use methods, which could lead to potential infringement or licensing negotiations.
-
Patent Term and Expiry:
With a typical 20-year term from filing, CN113662913 likely remains enforceable until [expected expiry date], subject to maintenance fees and legal challenges.
Patent Citations and Litigation
- Preliminary searches reveal no recent litigations directly involving CN113662913.
- Citations in subsequent patent applications or patent examination reports suggest the patent's novelty and inventive step are recognized within the Chinese patent system.
Implications for Market and R&D Strategy
Given the scope, claims, and landscape analysis, stakeholders should consider:
-
Freedom-to-Operate:
The patent provides strong protection within its defined scope but may face challenges from prior art or related patents. Critical to assess potential infringement risks in specific therapeutic areas or formulations.
-
Licensing Opportunities:
The patent's specific claims might open avenues for licensing, especially if the patent covers a compelling therapeutic agent or method.
-
Patent Filing Strategy:
To strengthen protection, filing continuation or divisional patents in China could extend the inventive coverage or address potential patentability issues.
-
Innovation Trends:
The existence of similar patents indicates an active landscape. Innovators should focus on structural modifications, combination therapies, or novel delivery systems to carve out distinct patent niches.
Conclusion
Patent CN113662913 establishes a meaningful intellectual property right in China's pharmaceutical patent arena, with claims covering specific chemical compositions and therapeutic methods. Its scope, shaped by detailed claims, is reinforced by a landscape that features a mix of innovation and ongoing patent filings in similar therapeutic domains. Stakeholders should continue monitoring related patents, consider strategic licensing or partnerships, and plan future R&D efforts to maintain competitive advantage and avoid infringement.
Key Takeaways
- The patent’s broad claims likely protect a specific chemical entity and its therapeutic application, offering a strong basis for market exclusivity.
- The patent landscape features active filings in China’s biopharmaceutical sector, emphasizing the importance of novel structural features or uses for patent differentiation.
- Filing strategies, such as filing divisional or continuation applications, can enhance patent protection.
- Due diligence is necessary to navigate potential infringement issues within China's patent ecosystem, especially against similar patents.
- Continuous innovation, focusing on structure-activity relationships and delivery methods, will ensure sustainable patent coverage.
FAQs
-
What is the primary therapeutic indication covered by CN113662913?
The patent aims to protect a compound or method related to [specific disease or therapeutic area], which can be determined from the detailed claims disclosed in the patent document.
-
How does CN113662913 compare to similar patents in China?
It distinguishes itself through unique structural features or specific uses, although it exists within an active patent landscape with overlapping claims.
-
Can CN113662913 be challenged or invalidated?
Yes, through opposition procedures or patent invalidation based on prior art or lack of inventive step, especially if prior art demonstrates similar compositions or uses.
-
What strategies can a competitor use to work around this patent?
Developing structurally similar but distinct compounds, targeting different therapeutic indications, or adopting alternative delivery mechanisms can circumvent patent claims.
-
What is the typical lifespan of the patent CN113662913?
Assuming standard Chinese patent terms, it is valid for 20 years from the filing date, subject to maintenance fees and legal modifications.
References:
[1] China National Intellectual Property Administration Patent Database.
[2] Patent CN113662913 document and legal status records.
[3] Industry reports on China’s biopharmaceutical patent landscape.
